HEMLIBRA is a MEDSAFE registered prescription medicine.
Roche is working closely with all relevant stakeholders to achieve the earliest possible funding for people with haemophilia A with inhibitors.
Current funding application time-line for HEMLIBRA in people with haemophilia A with inhibitors.
HEMLIBRA submitted for registration to Medsafe under priority review October 2017
HEMLIBRA received Medsafe registration in August 2018
HEMLIBRA submitted to the Haematology sub committee January 2019
HEMLIBRA given high priority by the Haematology subcommittee January 2019
HEMLIBRA submitted to the PTAC meeting May 2019
PTAC confirm the high priority recommendation by the Haematology subcommittee May 2019
Roche begin negotiations with PHARMAC for funding of HEMLIBRA in People with Haemophilia A and inhibitors September 2019
PTAC = Pharmacology and Therapeutics Advisory Committee